Cancer clinical trials in the region Île-de-France

355 currently recruiting clinical trials

If you are a doctor and would like find matching clinical trials for you patients, create an account or log in

If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial

Phase 2 Lung cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Stomach and esophageal cancer

#NCT03175224

[SPARTA] APL-101 chez des patients atteints de tumeurs solides avancées avec anomalies de MET - Cohortes C, D et F

Locally Advanced Metastatic MET 1 2 3 or more

ALK BRAF EGFR KRAS G12C KRAS non G12C NTRK-1/2/3 RET ROS-1 Systemic Treatment-Naive Targeted therapy

Gustave Roussy (Villejuif), Hôpital Bichat - Claude Bernard - AP-HP (Paris)

Apollomics

Phase 2 Lung cancer

#NCT05498428

[PALOMA-2] Étude de l'AMIVANTAMAB chez des patients atteints d'un cancer du poumon non à petites cellules muté EGFR - Cohortes 1, 5 et 6

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive

Gustave Roussy (Villejuif), Institut Curie - Paris (Paris)

Janssen

Phase 2 Lung cancer

#NCT05498428

[PALOMA-2] Étude de l'AMIVANTAMAB chez des patients atteints d'un cancer du poumon non à petites cellules muté EGFR - Cohortes 2, 3 et 3b

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR None 1 2 Systemic Treatment-Naive Targeted therapy

Gustave Roussy (Villejuif), Institut Curie - Paris (Paris)

Janssen

Phase 2 Lung cancer

#NCT05498428

[PALOMA-2] Étude de l'AMIVANTAMAB chez des patients atteints d'un cancer du poumon non à petites cellules muté EGFR - Cohorte 7

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Locally Advanced Metastatic EGFR 1 Targeted therapy Bispecific T-cell engager antibodies

Gustave Roussy (Villejuif), Institut Curie - Paris (Paris)

Janssen

Phase 2 Lung cancer

#NCT05498428

[PALOMA-2] Étude de l'AMIVANTAMAB chez des patients atteints d'un cancer du poumon non à petites cellules muté EGFR - Cohorte 4

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic 1 2 3 or more Bispecific T-cell engager antibodies

Gustave Roussy (Villejuif), Institut Curie - Paris (Paris)

Janssen

Phase 2 Kidney cancer

#NCT05865730

Étude d'Oncobax®-AK chez des patients atteints de tumeurs solides avancées

Clear cell carcinoma Locally Advanced Metastatic

Gustave Roussy (Villejuif)

EverImmune

Phase 2 Lung cancer

#NCT05865730

Étude d'Oncobax®-AK chez des patients atteints de tumeurs solides avancées

NSCLC (Non-Small Cell Lung Cancer) Non-squamous NSCLC Metastatic PDL1 Positive (>= 50%)

Gustave Roussy (Villejuif)

EverImmune

Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer

#NCT06333314

[Pan-MSI-ACSE] DOSTARLIMAB pour le cancer localement avancé ou métastatique (non colorectal/non endométrial) avec tumeur dMMR/MSI

Neuroendocrine tumor MSI/dMMR Systemic Treatment-Naive

Immunotherapy Radiotherapy

Hôpital Henri-Mondor AP-HP (Créteil), Gustave Roussy (Villejuif), Hôpital Saint Antoine AP-HP (Paris)

UNICANCER

Phase 2 Breast cancer

#NCT04423029

Étude du DF6002 seul vs association DF6002 + NIVOLUMAB chez les patients atteints de tumeurs solides localement avancées ou métastatiques

HER2 Negative HR Negative Locally Advanced Metastatic

Systemic Treatment-Naive

Hôpital Saint Louis AP-HP (Paris)

Bristol-Myers Squibb

Phase 2 Lung cancer

#NCT04423029

Étude du DF6002 seul vs association DF6002 + NIVOLUMAB chez les patients atteints de tumeurs solides localement avancées ou métastatiques

SCLC (Small Cell Lung Cancer) NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic

Systemic Treatment-Naive

Hôpital Saint Louis AP-HP (Paris)

Bristol-Myers Squibb